294 related articles for article (PubMed ID: 24729718)
1. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.
Hedari CP; Khinkarly RW; Dbaibo GS
Infect Drug Resist; 2014; 7():85-99. PubMed ID: 24729718
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.
Ghanem S; Hassan S; Saad R; Dbaibo GS
Expert Opin Biol Ther; 2013 Aug; 13(8):1197-205. PubMed ID: 23815506
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
Dbaibo G; El-Ayoubi N; Ghanem S; Hajar F; Bianco V; Miller JM; Mesaros N
Drugs Aging; 2013 May; 30(5):309-19. PubMed ID: 23494214
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of Infanrix™ when co-administered with meningococcal MenACWY-TT conjugate vaccine in toddlers primed with MenHibrix™ and Pediarix™.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Baccarini C; Miller JM
Vaccine; 2015 Feb; 33(7):924-32. PubMed ID: 25305567
[TBL] [Abstract][Full Text] [Related]
5. Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix
Dhillon S; Pace D
Drugs; 2017 Nov; 77(17):1881-1896. PubMed ID: 29094312
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.
Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J
Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281
[TBL] [Abstract][Full Text] [Related]
7. A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine.
Ruiz Garcia Y; Abitbol V; Pellegrini M; Bekkat-Berkani R; Soumahoro L
Infect Dis Ther; 2022 Apr; 11(2):639-655. PubMed ID: 34591258
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
[TBL] [Abstract][Full Text] [Related]
9. Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial.
Merino Arribas JM; Carmona Martínez A; Horn M; Perez Porcuna XM; Otero Reigada MD; Marès Bermúdez J; Centeno Malfaz F; Miranda M; Mendez M; Garcia Cabezas MA; Wittermann C; Bleckmann G; Fischbach T; Kolhe D; van der Wielen M; Baine Y
Pediatr Infect Dis J; 2017 Apr; 36(4):e98-e107. PubMed ID: 28002359
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers.
Bona G; Castiglia P; Zoppi G; de Martino M; Tasciotti A; D'Agostino D; Han L; Smolenov I
Vaccine; 2016 Jun; 34(29):3363-70. PubMed ID: 27181507
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
[TBL] [Abstract][Full Text] [Related]
13. Meningococcal Group A, C, W, and Y Tetanus Toxoid Conjugate Vaccine: A Review of Clinical Data in Adolescents.
Serra LC; York LJ; Balmer P; Webber C
J Adolesc Health; 2018 Sep; 63(3):269-279. PubMed ID: 30236996
[TBL] [Abstract][Full Text] [Related]
14. Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae-N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy.
Leonardi M; Latiolais T; Sarpong K; Simon M; Twiggs J; Lei P; Rinderknecht S; Blatter M; Bianco V; Baine Y; Friedland LR; Miller JM
Vaccine; 2015 Feb; 33(7):933-41. PubMed ID: 25152325
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).
Croxtall JD; Dhillon S
Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age.
Marshall GS; Pelton SI; Robertson CA; Oster P
Hum Vaccin Immunother; 2022 Nov; 18(6):2099142. PubMed ID: 35947774
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines.
Jonker EFF; van Ravenhorst MB; Berbers GAM; Visser LG
Vaccine; 2018 Jun; 36(26):3727-3732. PubMed ID: 29778515
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial and postmarketing safety experience with MenACWY-TT, a meningococcal group A, C, W, and Y tetanus conjugate vaccine.
Serra L; Webber C; Burman C; Bueti P; Gorruso M; Mather S
Vaccine; 2022 Nov; 40(49):7014-7021. PubMed ID: 36283896
[TBL] [Abstract][Full Text] [Related]
19. Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants.
Martinón-Torres F; Serra L; Safadi MAP
Expert Rev Vaccines; 2020 Apr; 19(4):313-325. PubMed ID: 32250710
[TBL] [Abstract][Full Text] [Related]
20. Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y.
Cooper B; DeTora L; Stoddard J
Expert Rev Vaccines; 2011 Jan; 10(1):21-33. PubMed ID: 21162617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
